이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

LUCINAE Registry: Thoracic Cancers During Pregnancy (LUCINAE)

2026년 7월 7일 업데이트: Oncology Institute of Southern Switzerland

LUCINAE: LUng and Thoracic Cancers In pregNAncy rEgistry

The LUCINAE Registry is an international, multicenter observational study collecting data on patients with thoracic cancers (including lung cancer) who are expecting a child. This includes women diagnosed during pregnancy, women who become pregnant during or after cancer, and men receiving cancer treatment at the time their partner conceives.

Because thoracic cancers during pregnancy are rare, there is limited information to guide clinical decisions. This registry aims to describe patient characteristics, diagnostic approaches, treatments, and maternal and fetal outcomes. Data are collected retrospectively and prospectively from participating centers.

The results of this registry are expected to improve understanding of thoracic cancers in this setting and support the development of future clinical recommendations.

연구 개요

상태

모병

정황

상세 설명

The LUCINAE Registry (LUng and thoracic Cancers In pregNAncy rEgistry) is an international, multicenter registry with retrospective and prospective (ambispective) data collection.

The incidence of cancers in younger individuals is increasing, and due to delayed maternal age and other factors, more patients are diagnosed with cancer during pregnancy or become pregnant during or after cancer treatment. Thoracic cancers during pregnancy are rare events, but they are associated with high maternal morbidity and mortality and may have important implications for fetal outcomes.

Currently, there is a lack of specific clinical guidelines for the management of thoracic cancers during pregnancy, and limited data are available regarding the safety and outcomes of anticancer treatments in this setting. Existing registries are not specific for thoracic malignancies, and available evidence is based on a limited number of reported cases.

The LUCINAE Registry aims to collect comprehensive data on biologically female and male patients with thoracic cancers who are expecting a child. The primary objective is to describe clinical and biological characteristics, family history, treatments, and maternal and fetal outcomes.

The study includes two cohorts:

Cohort A (retrospective): patients included after death, with data collected from medical records.

Cohort B (prospective): patients currently treated or diagnosed during the enrollment period, with longitudinal follow-up and periodic data updates.

Eligible participants include women diagnosed with thoracic cancer during pregnancy, women who become pregnant during active disease or within 5 years after treatment, and men receiving active oncological treatment at the time their partner conceives.

Data collected include patient characteristics (demographics, medical history, genetic information), tumor characteristics (stage, histology, biomarker status), diagnostic procedures, treatment details (including systemic therapies, surgery, and radiotherapy), pregnancy characteristics, complications, and maternal and fetal outcomes. Follow-up data are collected at multiple timepoints up to 5 years after delivery, when available.

Analyses will be primarily descriptive and will evaluate clinical and biological characteristics, treatment patterns, and outcomes. Correlation analyses between treatments and outcomes will also be performed. The study does not impose any intervention, and all treatment decisions are made by the treating physicians.

The registry is intended to improve understanding of thoracic cancers in the context of pregnancy, to support future research, and to contribute to the development of clinical management strategies for this patient population.

연구 유형

관찰

등록 (추정된)

100

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

이름: Martina Imbimbo
전화번호: +41918119631
이메일: Martina.Imbimbo@eoc.ch

연구 연락처 백업

이름: Luigi Tortola
전화번호: +41 91 811 96 68
이메일: luigi.tortola@eoc.ch

연구 장소

스위스
- - Baden, 스위스
    - 모병
    - Kantonsspital Baden
    - 연락하다:
      
      Sacha Rothschild, Site Investigator
  - Bellinzona, 스위스
    - 모병
    - Istituto Oncologico della Svizzera Italiana (IOSI)
    - 연락하다:
      
      Martina Imbimbo, Project Leader
  - Geneva, 스위스
    - 모병
    - Geneva University Hospital (HUG)
    - 연락하다:
      
      Alfredo Addeo, Site Investigator
  - Winterthur, 스위스
    - 모병
    - Kantonsspital Winterthur
    - 연락하다:
      
      Laetitia Mauri, Site Investigator

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

성인
고령자

건강한 자원 봉사자를 받아들입니다

아니

샘플링 방법

비확률 샘플

연구 인구

The study will include all pregnant biological female patients, of any ethnicity, with a diagnosis of thoracic cancer at any stage and men with a diagnosis of thoracic cancer who were undergoing active oncological treatment at the time their partner conceived their child.

설명

Inclusion Criteria:

1. All patients with a diagnosis of thoracic cancer (including lung cancer, mesothelioma, thymic epithelial tumors, neuroendocrine tumors or sarcoma of the thorax and other rare thoracic entities) and pregnancy (positive pregnancy test) including:
1. Patients receiving a diagnosis of thoracic cancer during pregnancy
2. Patients who became pregnant while having active thoracic cancer
3. Patients previously treated for a thoracic cancer and becoming pregnant in the 5 years following end of treatment OR Men with a diagnosis of thoracic cancer (including lung cancer, mesothelioma, thymic epithelial tumors, neuroendocrine tumors or sarcoma of the thorax and other rare thoracic entities), who were undergoing active oncological treatment at the time their partner conceived their child.
2. Available information about pregnancy outcomes
3. Age ≥ 18 years

Exclusion Criteria:

1. Patient missing data about thoracic cancer stage and diagnosis
2. For retrospective patients, documented refusal to the use of clinical data for research purposes

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

코호트 및 개입

그룹/코호트 그룹/코호트 생물 의학 또는 건강 결과에 대해 평가되는 관찰 연구의 참가자 그룹 또는 하위 그룹입니다.
Cohort A Retrospective patients: patients who are included in the registry only after death.
Cohort B Prospective patients: patients who are currently treated at the participating site or will be diagnosed during the enrollment

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정	측정값 설명	기간
Timing of diagnosis 기간: At the moment of patient enrolment	Timing of cancer diagnosis with respect to the onset of pregnancy.	At the moment of patient enrolment
Modality of diagnosis 기간: At the moment of patient enrolment	Method used for cancer diagnosis.	At the moment of patient enrolment
Duration of treatment 기간: Throughout study participation, up to 5 years after delivery.	Duration of the treatment received during the pregnancy	Throughout study participation, up to 5 years after delivery.
Maternal outcome 기간: At the conclusion of pregnancy.	Survival of the mother at the end of gestation.	At the conclusion of pregnancy.
Fetal outcome 기간: At the conclusion of pregnancy.	Survival of the fetus at the end of gestation.	At the conclusion of pregnancy.

2차 결과 측정

결과 측정	측정값 설명	기간
Parental overall survival 기간: From thoracic cancer diagnosis until 5 years after delivery.	Overall survival of biologically female and male thoracic cancer patients included in the registry, defined as time from thoracic cancer diagnosis to death from any cause.	From thoracic cancer diagnosis until 5 years after delivery.
Offspring's overall survival 기간: From birth until 5 years after birth.	Overall survival of the offspring of enrolled parents, defined as time from birth to death from any cause.	From birth until 5 years after birth.
Pregnancy complications 기간: From pregnancy diagnosis to 1 month after delivery.	Incidence of complications associated with the pregnancy.	From pregnancy diagnosis to 1 month after delivery.
Gestational age at delivery 기간: At the conclusion of pregnancy.	Gestational age of the fetus at the moment of delivery.	At the conclusion of pregnancy.
Congenital abnormalities 기간: From birth to 30 days after birth.	Proportion of newborns diagnosed with congenital abnormalities.	From birth to 30 days after birth.
Neonatal intensive care unit (NICU) admission 기간: From birth to 30 days after birth.	Proportion of newborns admitted to neonatal intensive care unit after birth.	From birth to 30 days after birth.
Apgar score 기간: Measured 1 minute and 5 minutes after birth.	Measurement of Apgar score to assess the newborn's vital signs and immediate need for medical intervention.	Measured 1 minute and 5 minutes after birth.
Oncologic treatment exposure 기간: Throughout pregnancy until 5 years after delivery.	Type, timing, and toxicity of anticancer treatments administered during and after pregnancy.	Throughout pregnancy until 5 years after delivery.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Oncology Institute of Southern Switzerland

협력자

Clinical Trial Unit Ente Ospedaliero Cantonale

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 6월 1일

기본 완료 (추정된)

2035년 12월 1일

연구 완료 (추정된)

2035년 12월 1일

연구 등록 날짜

최초 제출

2026년 5월 11일

QC 기준을 충족하는 최초 제출

2026년 7월 7일

처음 게시됨 (실제)

2026년 7월 13일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)